Biomm

Biomm Equity Growth

The Year-over-Year Equity Growth of Biomm (BIOM3.SA) as of Nov 11, 2026 is 19.30 %. In the previous year, Year-over-Year Equity Growth was 113.75 % — a change of -83.03% (lower).

Equity Growth

19.30 %

YoY

-83.03%

Last updated:

Year-over-Year Equity Growth of Biomm is 2025 19.30 % . Year-over-Year Equity Growth of Biomm was 2024 113.75 % . It decreases by -83.03% lower compared to the previous year.

The Biomm Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
78.90 BRL
Jan 1, 2019
44.74 BRL
Jan 1, 2020
24.70 BRL
Jan 1, 2021
-41.72 BRL
Jan 1, 2022
42.59 BRL
Jan 1, 2023
-22.73 BRL
Jan 1, 2024
113.75 BRL
Jan 1, 2025
19.30 BRL
The Biomm Equity Growth history
YEAREquity GrowthYoY
19.30 %-83.03%
113.75 %-600.39%
-22.73 %-153.38%
42.59 %-202.07%
-41.72 %-268.95%
24.70 %-44.81%
44.74 %-43.29%
78.90 %-884.81%
-10.05 %-76.47%
-42.73 %-670.18%
7.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Year-over-Year Equity Growth of Biomm is 19.30 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Biomm since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Biomm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biomm

All Key Metrics — Biomm